China NT Pharma seeks court revocation of RMB 92 million arbitration award

• China NT Pharma sought court revocation of a July 17, 2026, arbitration award imposing approximately RMB 92 million in liabilities.
• The award covers the company and jointly liable parties; the company alleges material factual and legal errors.
• Wholly owned subsidiary NT Pacific sued Beijing Kangchen, seeking mandatory repurchase of its approximately 25.3% stake over alleged prejudice to minority shareholders.
• Beijing Konruns Pharmaceutical is named as a third party in the litigation, which follows disputes over the Miacalcic asset transaction.
• Both court applications were pending acceptance and hearing as of October 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China NT Pharma Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261030-12391246), on October 30, 2026, and is solely responsible for the information contained therein.